STOCK TITAN

Enveric Biosciences Inc - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.

Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.

Our news collection prioritizes accuracy and timeliness, offering:

• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news

Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced groundbreaking research detailing the isolation of a novel indolethylamine N-methyltransferase from the cane toad (Rhinella marina). This discovery enables a new bioproduction platform for developing psychedelic-inspired drug candidates aimed at treating psychiatric disorders like anxiety and depression. The research was conducted by the University of Calgary and led by Dr. Peter Facchini. Enveric aims to begin human clinical trials for their lead product, EB-373, for anxiety treatment, reflecting their commitment to innovate in mental health therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.8%
Tags
none
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) has appointed Kevin Coveney, CPA, as Chief Financial Officer effective March 13, 2023. With over 30 years of experience in finance and operations within the biotechnology sector, Coveney aims to lead the company's financial and capital market activities. He has a proven track record of executing growth strategies in previous roles at various biotech firms. Coveney's appointment comes at a crucial time as Enveric advances its EVM201 and EVM301 product series targeting mental health issues. As part of his induction, Coveney will receive restricted stock units convertible to 26,500 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
management
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced the appointment of Lynn Gallant as Vice President, Clinical Operations, effective February 22, 2023. Gallant brings over 25 years of experience in clinical operations and trial management, previously holding leadership roles at BlueRock Therapeutics and Bioverativ. She will oversee the clinical development of Enveric’s EVM201 and EVM301 product platforms. The company plans to initiate a clinical trial for its lead drug candidate, EB-373, targeting anxiety disorders. Enveric's focus is on developing novel therapeutics for mental health, leveraging its unique Psybrary™ drug discovery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
none
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on developing small-molecule therapeutics for anxiety, depression, and addiction disorders, announces CEO Joseph Tucker, Ph.D., will present at the 6th Annual Growth Conference by Gravitas Securities Inc. on March 2, 2023 in Vancouver, British Columbia. Dr. Tucker's presentations include a Healthcare Panel at 1:40 p.m. PST and a Company Presentation at 2:00 p.m. PST. He will also hold one-on-one meetings with investors to discuss Enveric’s strategies, achievements, and future milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on innovative therapeutics for mental health disorders, announced CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference from February 6-9, 2023, in New York City. The presentation on February 6 at 3:00 p.m. EST will highlight the company's clinical development strategy and recent achievements. Enveric aims to address anxiety, depression, and addiction through its proprietary platform, The Psybrary™, with a focus on its EVM201 Series, particularly the EB-373 treatment for anxiety disorders. One-on-one investor meetings will also take place during the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced its participation at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during the 41st Annual J.P. Morgan Health Care Conference in San Francisco from January 9-12, 2023. Dr. Joseph Tucker, CEO, will present the company's advancements in therapeutics addressing anxiety, depression, and addiction disorders. The Neuroscience Forum presentation is scheduled for January 8 at 1:30 PM PT, while the Biotech Showcase will take place on January 10 at 10:00 AM PT. Enveric leverages its unique Psybrary™ platform to develop innovative small-molecule therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
conferences
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced the confidential submission of a Form S-1 draft registration statement to the SEC for a spin-off of its cannabinoid pipeline into a subsidiary named Akos Biosciences. The spin-off aims to enhance strategic focus and unlock potential value, allowing each entity to raise capital independently. Shareholders will own a majority of Akos post-separation, which is expected to list on Nasdaq in the first half of 2023. The dividend will be taxable for U.S. federal income purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
none
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotech firm focused on developing small-molecule therapeutics for anxiety, depression, and addiction, announced the participation of President & COO Avani Kanubaddi in A.G.P.’s Virtual Biotech Conference from November 30 to December 1, 2022. This conference aims to connect Enveric's management with investors and stakeholders. Interested parties can schedule one-on-one meetings by contacting A.G.P. or KCSA Strategic Communications. For more details, visit www.enveric.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on developing innovative therapeutics for anxiety, depression, and addiction, announces CEO Dr. Joseph Tucker's participation in the Wonderland conference in Miami, FL, from November 3-5, 2022. Dr. Tucker will speak on the panel entitled Synthetic vs Natural Debate on November 5 at 12:00 p.m. ET. Interested parties can schedule one-on-one meetings with Enveric's management by contacting KCSA Strategic Communications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
conferences
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) has announced the nomination of EB-373 as the lead candidate from its EVM201 program, targeting anxiety disorders. This milestone coincides with preclinical data presented at the International Neurology & Brain Disorders Conference. EB-373 is set to advance through key preclinical studies aimed at filing an IND application with the FDA in late 2023. The company also disclosed the discontinuation of the first-generation EVM101 program due to promising results from its newer drug candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
none
Enveric Biosciences Inc

Nasdaq:ENVB

ENVB Rankings

ENVB Stock Data

2.89M
2.47M
0.07%
7.16%
64.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
NAPLES